Altrafin AG’s Palantir PLTR Stock Holding History

Altrafin AG’s Portfolio PLTR Stock Details PLTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,334	Closed	-$341K	–	54
2026 Q1	$341K	Buy	2,334 +993	+74%	+$152K	0.12%	47
2025 Q4	$238K	Sell	1,341 -1,156	-46%	-$209K	0.08%	46
2025 Q3	$455K	Sell	2,497 -1	-0%	-$162	0.14%	41
2025 Q2	$341K	Buy	+2,498	New	+$293K	0.12%	47
2022 Q3	–	Sell	-63,539	Closed	-$576K	–	75
2022 Q2	$576K	Sell	63,539 -15,111	-19%	-$149K	0.31%	60
2022 Q1	$1.08M	Buy	78,650 +645	+0.8%	+$8.6K	0.42%	52
2021 Q4	$1.42M	Buy	+78,005	New	+$1.72M	0.51%	50

Other funds holding PLTR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Altrafin AG's PLTR Position: Q2 2026 in Review

Altrafin AG sold out of Palantir (PLTR) in Q2 2026, closing a stake of 2,334 shares — an estimated $341K sold.

Altrafin AG first reported a position in PLTR in Q4 2021 and held it in 7 quarters. The position peaked at $1.42M in Q4 2021. 2,851 funds tracked by Wall St. Rank hold PLTR as of Q2 2026.

Altrafin AG reported no remaining Palantir position as of Q2 2026 after selling out during the quarter.
Altrafin AG sold 2,334 Palantir shares in Q2 2026, an estimated $341K.
Altrafin AG first reported a position in Palantir in Q4 2021 and held it in 7 quarters.
Altrafin AG's Palantir position peaked at $1.42M in Q4 2021.
2,851 funds tracked by Wall St. Rank held Palantir as of Q2 2026.

Based on Altrafin AG's 13F filing for Q2 2026, filed 15 Jul 2026.